Native hG-CSF Purification via Periplasmic Secretion and Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying human granulocyte-colony stimulating factors (hG-CSFs) from recombinant E. coli face challenges such as low yield, contamination with impurities, and the need for complex purification processes, especially when producing non-glycosylated forms without methionine at the N-terminus, which are essential for native protein production.
Innovation Solution
A method involving culturing hG-CSF-expressing recombinant E. coli, followed by acid precipitation, cation exchange chromatography, hydrophobic-interaction chromatography, and anion exchange chromatography to achieve high purity and yield of native hG-CSFs without additional activation processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If hG-CSF is produced in E. coli using conventional methods, then production cost is reduced, but the protein forms insoluble inclusion bodies requiring refolding which causes yield loss and potency reduction
Solution Approach 1:
The signal peptide is engineered in advance to direct hG-CSF secretion into the periplasmic space where oxidative conditions exist, preventing inclusion body formation before it occurs. This preliminary positioning avoids the need for refolding and associated yield losses.
Solution Approach 2:
The periplasmic space acts as an intermediary environment with oxidative conditions that prevent improper disulfide bond formation. By secreting hG-CSF into this intermediate space rather than cytoplasm, the protein maintains proper folding and activity without requiring subsequent refolding procedures.
2Manufacturing precision
If a complicated purification process is used to remove impurities, then purity is improved, but process complexity and time increase
Solution Approach 1:
The signal peptide is removed (cleaved off) from the N-terminus of hG-CSF after secretion, extracting the problematic portion that causes impurity issues. This leaves the native-form hG-CSF without methionine residue, simplifying subsequent purification requirements.
Solution Approach 2:
The signal peptide sequence is modified to change its properties - specifically making it more hydrophobic and basic. This parameter change allows the signal peptide to be more effectively removed and simplifies the purification process by creating a clearer separation between signal peptide and target protein.
3Productivity
If signal peptide is modified to increase expression rate, then productivity is improved, but purification difficulty increases due to altered protein properties
Solution Approach 1:
Only the signal peptide portion is modified with specific properties (hydrophobic and basic residues), while the hG-CSF portion remains unchanged. This localized modification allows high expression rates without affecting the purification of the target protein, as the modified signal peptide can be selectively removed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the efficient purification of native hG-CSFs with high purity and yield, effectively removing impurities and maintaining physiological activity, suitable for pharmaceutical use, and significantly improves the productivity of hG-CSFs in large-scale production.
Implementation Method 1
treating the supernatant obtained in step (b) with an acid to separate the resulting precipitate by filtration
Implementation Method 2
applying a filtrate obtained in step (c) to cation exchange chromatography
Implementation Method 3
applying an eluate obtained in step (d) to hydrophobic-interaction chromatography
Implementation Method 4
applying an eluate obtained in step (e) to anion exchange chromatography
Implementation Method 5
culturing an hG-CSF-expressing recombinant E. coli to obtain a cell pellet by centrifugation
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present invention provides a method for purifying a large amount of human granulocyte-colony stimulating factors (hG-CSFs) from a recombinant E. coli with high yield and purity. According to the method of the present invention, human granulocyte-colony stimulating factor, identical to the native form expressed in the human body, can be easily purified with high yield and purity without an additional activation process. In particular, according to the purification method of the present invention, hG-CSF variants expressed in E. coli are efficiently removed to obtain physiologically active hG-CSFs with high purity.